Aurum USA

Creating ahealthier worldfor future generations

Who We Are

IMPAACT4 TB is a groundbreaking global initiative designed to slow and stop the increase of new TB cases by preventing latent TB infections—the hidden stage fuelling the global TB epidemic. IMPAACT4TB introduced safer, shorter treatment options that make treatment easier and more accessible to the most vulnerable.

Led by the Aurum Institute, the IMPAACT4TB consortium targeted people living with HIV, children under five, and other close contacts of TB patients across 12 high-burden countries accounting for half of the world’s TB burden. The rollout of short-course preventative therapy dramatically reduced the number of new TB cases and saved lives.

Aurum USA is the Washington DC-based, non-profit, arm of the organization’s global network. Co-led by dedicated in-country staff, Aurum USA provides:

We’ve led more than 224 clinical trials and research studies over the past 18 years, advancing scientific breakthroughs across key public health priorities:

Expert management of Africanbased projects on behalf of grant or donor agencies and individuals, including guiding program implementation, monitoring and evaluation, and audit and reporting.

A US base for collaborators (academic institutions, researchers, businesses) on projects in sub-Saharan Africa, enabling an effective and efficient administrative hub that supports US-based participants and adjunct activities.

Aurum USA Personnel

Adjunct Professor Dave Clark

is the Group Chief Executive Officer (CEO) and an executive director and board member of The Aurum Institute.

Prof. Edward is the Group Chief Operating Officer

at The Aurum Institute. He has been a basic sciences researcher since 2000 and has been involved in clinical research management since 2005. He is highly experienced in working with various international donors and delivering various projects simultaneously.

Margaret McCluskey

serves as Aurum USA’s Senior Strategic Advisor, and her background includes leading HIV vaccine research for the United States Agency for International Development, the Vaccine Research Center at the National Institutes of Health, and the Johns Hopkins University

John Hamilton

is the US Lead for Aurum USA. His experience includes managing grants, (Country Director for EQUIP Malawi), and academic institutions, (Assistant Provost - Chief of Staff position – for UCLA).

Our Impact

13 200 000 Patient courses of
3HP have been purchased across
104 countries worldwide

Price reduction of 3HP
from $72 in 2017 to
$9,99 in 2024

Protecting children from TB – the Dolphin Kids Study

Implemented under the IMPAACT4TB project, Dolphin Kids helped rewrite the story of TB prevention for children living with HIV. The study piloted child-friendly research into the interaction of once-weekly TB preventative treatment (3HP) alongside Dolutegravir, a key HIV medication.

Children in the study received regular health check-ups, close monitoring and support from their caregivers over 12 weeks of treatment and eight weeks of follow-up. In addition, support for their caregivers helped families to gain peace of mind while preventing children from TB.

Mothers like Babalwa Ngxowa, who enrolled her son Thami, faced feelings of hope and fear. “I was scared,” she admits. “As a mom, you wouldn’t allow anything to happen to your kids.

They told me they were going to give my child some pills for TB prevention. I didn’t know about the outcomes or the side effects, but I knew that whatever they were doing, they were prepared for it.”

Aurum and the consortium are leading how paediatric TB prevention gives children living with HIV a stronger and healthier future.

Where We Work | Our Footprint

Contact Us: The Aurum Institute USA, 535 Park Avenue Apt 1-C, New York, NY 10065 John Hamilton, US Lead, jhamilton@auruminstitute.org, +13106896639